IMU-838

Vidofludimus Calcium Safely Reduced RRMS Brain Lesions

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…

1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeuticsā€™ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…

1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS

Immunic TherapeuticsĀ has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…

CALLIPER Trial for Progressive MS Enrolls First Patient

Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the companyā€™s two identically-designed Phase 3 trials, dubbed…

Trials of IMU-838 in RRMS, Progressive MS Start Later This Year

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medicationĀ IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…